Davita (DVA) Bonds Trading 1.6% Lower
An issue of Davita Inc (NYSE:DVA) debt fell 1.6% against its face value during trading on Friday. The high-yield issue of debt has a 5.125% coupon and will mature on July 15, 2024. The bonds in the issue are now trading at $96.75 and were trading at $98.50 last week. Price changes in a company’s debt in credit markets often anticipate parallel changes in its stock price.
Separately, William Blair restated a “buy” rating on shares of Davita in a research report on Wednesday, June 6th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $81.22.
DVA traded down $0.71 during trading on Friday, reaching $69.44. The stock had a trading volume of 1,342,274 shares, compared to its average volume of 1,562,297. The company has a market capitalization of $12.35 billion, a price-to-earnings ratio of 20.92, a price-to-earnings-growth ratio of 1.03 and a beta of 1.10. The company has a debt-to-equity ratio of 1.94, a current ratio of 2.94 and a quick ratio of 2.90. Davita Inc has a 1-year low of $52.51 and a 1-year high of $80.71.
In other Davita news, Director William L. Roper sold 1,505 shares of the company’s stock in a transaction on Tuesday, May 22nd. The stock was sold at an average price of $68.22, for a total value of $102,671.10. Following the transaction, the director now owns 46,733 shares of the company’s stock, valued at $3,188,125.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Pamela M. Arway sold 1,264 shares of the company’s stock in a transaction on Thursday, June 7th. The shares were sold at an average price of $68.76, for a total value of $86,912.64. Following the completion of the transaction, the director now directly owns 39,235 shares in the company, valued at approximately $2,697,798.60. The disclosure for this sale can be found here. Insiders sold 3,107 shares of company stock worth $211,976 in the last ninety days. 0.95% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its holdings in shares of Davita by 1.2% in the first quarter. Dimensional Fund Advisors LP now owns 2,762,205 shares of the company’s stock valued at $182,141,000 after buying an additional 32,357 shares in the last quarter. OppenheimerFunds Inc. increased its holdings in shares of Davita by 36.7% in the first quarter. OppenheimerFunds Inc. now owns 2,561,970 shares of the company’s stock valued at $168,937,000 after buying an additional 688,052 shares in the last quarter. Boston Partners increased its holdings in shares of Davita by 39.7% in the first quarter. Boston Partners now owns 2,036,058 shares of the company’s stock valued at $134,258,000 after buying an additional 578,242 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Davita by 239.9% in the fourth quarter. Millennium Management LLC now owns 2,024,308 shares of the company’s stock valued at $146,256,000 after buying an additional 1,428,810 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Davita by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 1,609,652 shares of the company’s stock valued at $116,051,000 after buying an additional 16,017 shares in the last quarter. 87.67% of the stock is currently owned by institutional investors.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.